Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Publication date: Jun 03, 2019

This study will investigate whether the use of talimogene laherparepvec (T-VEC) in combination with BRAF/MEK inhibitor will result in durable regional and distant recurrence free survival in the neoadjuvant setting for treatment of advanced nodal BRAF mutant melanoma.

Concepts Keywords
Acyclovir Carcinomatosus meningitis
Adjuvant Cervical carcinoma
Adrenal Metastasis
Adverse Event Prostatic intraepithelial neoplasia
Alanine Aminotransferase Infection
ALT Brain metastases
Anticoagulant Tumors
Anticoagulants Liver metastases
APTT Cutaneous primary melanoma
Aspartate Aminotransferase Adrenal pituitary insufficiency
AST Melanoma
Autoimmune Planned injection site
Bilirubin Immunosuppressive therapy
Biological Therapy Chemotherapy
Blood Radiotherapy
BRAF Hormonal therapy
Breast Immunosuppression
Breast Feeding Biological therapy
Central Nervous System Major surgery
Cervical Carcinoma Medicine
Chemotherapy Clinical medicine
Coagulation Cancer
Conglomerate Antineoplastic drugs
Corticosteroid Melanoma
Corticosteroids Biotechnology
Creatinine Experimental cancer treatments
Creatinine Clearance Oncolytic virus
Encephalitis Talimogene laherparepvec
Hemoglobin MEK inhibitor
Hepatitis Targeted therapy
HIV Ultrasound
Hormonal Therapy Chemotherapy
HSV
Immunodeficiency
Immunosuppressed
Immunosuppression
Immunosuppressive
Immunosuppressive Drugs
Immunosuppressive Therapy
Infection
Informed Consent
INR
Insulin
Intravenous
Keratitis
Latex Condom
Lesion
Liver
Malignancy
Malignant Melanoma
Melanoma
Meningitis
Metastases
Metastasis
Mutant
Mutation
Neoadjuvant
Nodal
Oncolytic Virus
Opportunistic Infection
Organ
PhD
Physical Exam
Pituitary Insufficiency
Platelet Count
Prednisone
Pregnancy Test
Prostate
Prothrombin
Radiotherapy
Serum
Severe Combined Immunodeficiency
Steroid
Steroids
Targeted Therapy
Therapeutic Range
Thyroxine
Topical
Transfusion
Tumor
Ultrasound
Urine
Urine Test
Vaccine
Viral
Virus

Semantics

Type Source Name
drug DRUGBANK Talimogene laherparepvec
gene UNIPROT BRAF
gene UNIPROT MAP2K7
gene UNIPROT NODAL
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH recurrence
drug DRUGBANK Aspartame
disease MESH metastasis
disease MESH Tumor
disease MESH growth
disease MESH Renal
drug DRUGBANK Creatinine
gene UNIPROT SLC17A5
drug DRUGBANK L-Alanine
drug DRUGBANK Prothrombin
disease MESH neurologic symptoms
drug DRUGBANK Prednisone
disease MESH meningitis
disease DOID meningitis
disease MESH autoimmune disease
disease DOID autoimmune disease
disease MESH pituitary insufficiency
disease DOID pituitary insufficiency
pathway BSID Primary immunodeficiency
disease MESH opportunistic infection
disease MESH complications
disease MESH infection
disease MESH herpetic keratitis
disease MESH encephalitis
disease DOID encephalitis
drug DRUGBANK Acyclovir
disease DOID cancer
drug DRUGBANK Tropicamide
gene UNIPROT EHD1
disease MESH skin cancer
disease DOID skin cancer
disease MESH carcinoma in situ
disease MESH ductal carcinoma in situ
disease DOID ductal carcinoma in situ
disease MESH Prostatic intraepithelial neoplasia
disease MESH prostate cancer
disease DOID prostate cancer
pathway BSID Prostate cancer
disease MESH HIV infection
disease DOID HIV infection
pathway BSID HIV Infection
gene UNIPROT NR4A2
gene UNIPROT ALG3
gene UNIPROT PDC

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *